Glaukos Corporation GKOS
Regular-session close
After hours · Nov 20, 5:23 PM ET
- YTD
- +110.18%
- 1 year
- +149.28%
5D -15.84 (-6.32%)
- Market cap
- 14.05B
- Revenue (ttm)
- 690.33M
- Profit margin
- -24.60%
- EPS (ttm)
- -2.95
- Shares out
- 59.20M
- Forward P/E
- 169.77
- YTD return
- +110.18%
- 1-year return
- +149.28%
- 50-day average
- 189.55
- 200-day average
- 149.71
- Volume
- 1.09M
- Avg volume
- 1.18M
- Open
- 238.87
- Previous close
- 238.10
- Day's range
- 233.40 – 244.55
- 52-week range
- 95.20 – 247.16
- Beta
- 0.68
- Analysts
- Strong Buy
- Price target
- 243.85 (+2.8%)
- Earnings date
- Feb 16, 2027
Key statistics
- Enterprise value
- 13.86B
- Price / sales
- 20.38
- Price / book
- 19.61
- Revenue growth
- 58.00%
- Free cash flow
- 52.60M
- Total cash
- 336.70M
- Total debt
- 105.15M
- Return on equity
- -22.84%
- Short % of float
- 9.17%
Fundamental scorecard
7 of 25 checks passed on GKOS’s reported financials
7of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 225.00
- Target (mean)
- 243.85
- Target (high)
- 270.00
- Strong buy3
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 0.4698.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 0.503 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | -0.09636 | 0.47 | +0.57 | +587.75% |
| Jul 29, 2026 | Jun 30, 2026 | -0.21054 | -0.14 | +0.07 | +33.50% |
| Apr 29, 2026 | Mar 31, 2026 | -0.30 | -0.18 | +0.12 | +40.00% |
| Feb 17, 2026 | Dec 31, 2025 | -0.22 | -0.28 | -0.06 | -27.27% |
| Oct 29, 2025 | Sep 30, 2025 | -0.27 | -0.16 | +0.11 | +40.74% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 16, 2026 | BTIG | main | Buy | Buy |
| Oct 29, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 29, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 29, 2026 | Citigroup | main | Buy | Buy |
| Oct 29, 2026 | Truist Securities | main | Buy | Buy |
| Oct 29, 2026 | Wells Fargo | main | Overweight | Overweight |
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- glaukos.com
News
Glaukos (NYSE:GKOS) COO Sells $11,063,955.44 in Stock
What Drove Glaukos Stock's 48% Rally Since the End of September?
2,747 Shares in Glaukos Corporation $GKOS Purchased by Ethic Inc. BTIG Maintains Buy on Glaukos, Raises Price Target to $252
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet HC Wainwright & Co. Maintains Buy on Glaukos, Raises Price Target to $248
JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $240
Citigroup Maintains Buy on Glaukos, Raises Price Target to $247
12 Health Care Stocks Moving In Thursday's Intraday Session Truist Securities Maintains Buy on Glaukos, Raises Price Target to $255
Your note
Sign in to keep a note on GKOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | Chief Executive Officer | Stock Gift | Mar 31, 2026 | 1,772,730 |
| FOLEY MARK J | Director | Stock Award(Grant) | May 27, 2026 | 60,267 |
| GILLIAM JOSEPH E. | President | Conversion of Exercise of derivative security | Nov 15, 2026 | 71,602 |
| HOFFMEISTER DAVID F | Director | Stock Award(Grant) | May 27, 2026 | 87,725 |
| KLIMAN GILBERT H. | Director | Conversion of Exercise of derivative security | Nov 3, 2026 | 37,406 |
| NAVRATIL TOMAS | Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 37,328 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.75% | 9,324,183 | 2.22B | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 7.82% | 4,629,687 | 1.10B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.58% | 3,303,897 | 785.30M | Sep 29, 2026 |
| Primecap Management Company | 5.20% | 3,076,200 | 731.18M | Sep 29, 2026 |
| FMR, LLC | 4.84% | 2,867,943 | 681.68M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.30% | 2,546,798 | 605.35M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.94% | 3,513,860 | 835.21M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 1,773,769 | 421.61M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 1,496,000 | 355.58M | Sep 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 2.50% | 1,478,020 | 351.31M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 1,280,092 | 304.27M | Jun 29, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.69% | 1,001,435 | 238.03M | Sep 29, 2026 |
